(ALONC) –
-
EDMOND DE ROTHSCHILD EQUITY STRATEGIES IV, Advised By ELYAN PARTNERS, Acquires a Majority Stake in ONCODESIGN SERVICES and Will File a Simplified Tender Offer on the Company's Remaining Shares
-
The General Meeting of Oncodesign Authorises the Allocation of Oncodesign Precision Medicine (OPM) Shares to Oncodesign Shareholders
-
Euronext Paris Authorises the Listing of Oncodesign Precision Medicine (OPM) Shares on Euronext Access + in Connection With the Allocation of OPM Shares to Oncodesign Shareholders
-
Servier Exercises the Exclusive Worldwide License Option of Their Collaboration Program With Oncodesign Precision Medicine (OPM) on Parkinson's disease
-
Oncodesign Precision Medicine (OPM) and Servier Announce a Strategic Collaboration to Discover New Therapeutic Targets for Pancreatic Cancer Treatment
-
Oncodesign Announces Its Results for the First Half of 2022: 28% Growth in Service Turnover
-
Oncodesign Continues to Grow With a Strong Increase in Its Service Activity’s Turnover in the First Half of 2022
-
ONCODESIGN Announces the Separation of Its Two Business Lines – Service and Biotech – and Its Entry Into Exclusive Negotiations With Elyan Partners for the Sale of a Majority Stake in ONCODESIGN (
-
Oncodesign Confirms Its Very Good Results in 2021 and an Attractive Outlook For 2022
-
SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors
-
SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors
-
Oncodesign Announces a 2021 Turnover of €31.3M, up by 22%, and Expects to Break Even
-
ONCODESIGN Announces Its 2022 Financial Agenda
-
Oncodesign Strengthens the Intellectual Property of ODS 101 in Treating Inflammatory Bowel Disease
-
Oncodesign Has Appointed Karine Lignel as Group Chief Development Officer
-
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates
-
Oncodesign Announces Its Results for the First Half of 2021
-
Oncodesign Announces a Sharp Increase in Turnover in the First Half Of 2021
-
Oncodesign Announces the Appointment of Aline Aubertin as an Independent Director of the Board of Directors
-
Oncodesign Provides an Update on Its Progress On RIPK2
-
Servier and Oncodesign Announce the Selection of a Preclinical Candidate as Part of Their Collaboration Targeting New Treatments for Parkinson’s Disease
-
InterSystems and Oncodesign Partner for the Optimization of Data Use to Enhance and Accelerate Drug Discovery Processes in Oncology
-
Oncodesign Records Positive Profitability for the Second Straight Year and Doubles Its Operating Profit Within the Context of the Global Health Crisis
-
Oncodesign Maintains Its Revenue and Operating Income at €38 Million in 2020 and is Anticipating an Operating Profit for the 2nd Straight Year, Within the Context of the Global Public Health Crisis
-
Oncodesign Announces a Share Ownership Plan for All Employees on the Occasion of the Group's 25th Anniversary
-
Oncodesign Announces Drug Discovery Cooperation With ViraTherapeutics, a Boehringer Ingelheim Subsidiary
-
Oncodesign Obtains €15.9 Million of Non-dilutive Financing in the Form of a State-Guaranteed Loan Within the Context of The COVID-19 Pandemic
-
Oncodesign: First-half 2020 Results
-
Oncodesign Announces a Capital Increase Reserved for the Company’s Management Committee
-
Oncodesign Reports Its First-half Revenue and a Strong Increase in Its Cash Position at June 30, 2020
-
Oncodesign and HitGen Announce a Strategic Partnership in Integrated Drug Discovery Services (IDDS)
-
Oncodesign Announces the Creation of its new “Artificial Intelligence” Business Unit and Appoints Stéphane Gerart as its Head
-
Oncodesign: Very Strong Improvement in Full-Year 2019 Results
-
Oncodesign to Host Conference Call Following the 2019 Full-Year Results Publication
-
Oncodesign and Servier Reach a Key First Milestone in Their Strategic Partnership on LRRK2 Inhibitors for Parkinson’s Disease
-
Oncodesign Announces a 33% Revenue Increase in 2019 and the Achievement of Financial Breakeven One Year Ahead of Schedule
-
Oncodesign Announces the Selection of Its First-in-Class RIPK2 Inhibitor Drug Candidate for Auto-immune and Inflammatory Diseases
-
Oncodesign: Publication of an Article Presenting Promising Results for the Treatment of Stone Man Syndrome (FOP)
-
Oncodesign: First-half 2019 Results
-
ONCODESIGN: Acceleration in Growth in the First Half of 2019, With Sales Rising 52% to €14 Million
-
Oncodesign Reaches a Key Milestone in the Development of Its RIPK2 Program
-
Oncodesign: 2018 Annual Results
-
Parkinson's Disease: Servier and Oncodesign Join Forces to Investigate New Line of Research
-
Oncodesign in 2018: Second Consecutive Year of Strong Growth in Operating Revenue, up 20% to €31.1 Million
-
Service Partnership Agreement between Oncodesign and Galderma
-
Oncodesign: Centre Georges François Leclerc Presents the Detailed Results of the First Two Stages of its Clinical Study in Lung Cancer at the EANM Congress
-
Oncodesign: 1st Half 2018 Results
-
Precision Medicine: Cap Digital and Medicen Paris-Region Team up with Oncodesign, Servier and Intersystems on Hu-PreciMED Project
-
Precision Medicine: Cap Digital and Medicen Paris-Region Team up with Oncodesign, Servier and Intersystems on Hu-PreciMED Project
-
Oncodesign Furthers Its Cooperation with Eisai, Started 12 Years Ago
Back to ALONC Stock Lookup
